Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
decrease costs » increased costs (Expand Search), decreased across (Expand Search)
Showing 1 - 20 results of 22,221 for search '(( significant decrease costs ) OR ( significant reduction (decrease OR increase) ))', query time: 0.38s Refine Results
  1. 1
    Average purchase costs of 3GCs and all oral antimicrobials per 100 patient-days from Phases 1–4.

    Average purchase costs of 3GCs and all oral antimicrobials per 100 patient-days from Phases 1–4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  2. 2
    Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  3. 3
    Trends in the incidence of extended-spectrum β-lactamase (ESBL)- producing Enterobacteriaceae per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of extended-spectrum β-lactamase (ESBL)- producing Enterobacteriaceae per 1000 patients, by month, during the pre-intervention period (Phase 1) and interven... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  4. 4
    Trends in the incidence of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional pe... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  5. 5
    Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  6. 6
    Trends in the incidence of penicillin-resistant <i>Streptococcus pneumoniae</i> (PRSP) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of penicillin-resistant <i>Streptococcus pneumoniae</i> (PRSP) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  7. 7
    Trends in the incidence of resistant <i>Haemophilus influenzae</i> per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of resistant <i>Haemophilus influenzae</i> per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  8. 8
    S1 Dataset -

    S1 Dataset - by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  9. 9
    Trends in the incidence of <i>Clostridioides difficile</i> infection (CDI) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of <i>Clostridioides difficile</i> infection (CDI) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phas... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  10. 10
    Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  11. 11
    Pop-up for oral 3GC prescription.

    Pop-up for oral 3GC prescription. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  12. 12
    Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  13. 13
    Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  14. 14
    Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  15. 15
    Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  16. 16
    Trends in the days of amoxicillin and amoxicillin-clavulanate therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of amoxicillin and amoxicillin-clavulanate therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  17. 17
    Cost-effectiveness acceptability curve.

    Cost-effectiveness acceptability curve. by Yiping An (20609789)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Reduction of NPIs by >50% may result increased transmission and significant mortality.

    Reduction of NPIs by >50% may result increased transmission and significant mortality. by Benjamin U. Hoffman (5470583)

    Published 2020
    Save to List
    Saved in:
  19. 19
    Key characteristics of non-healed DU wound records at adopted branches in 2022 and 2023.

    Key characteristics of non-healed DU wound records at adopted branches in 2022 and 2023. by Heba Tallah Mohammed (2822432)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Overall characteristics of wound records at adopted branches in 2022 and 2023.

    Overall characteristics of wound records at adopted branches in 2022 and 2023. by Heba Tallah Mohammed (2822432)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: